Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00275327 · ClinicalTrials.gov registry record
Mechanisms of Resistance and Molecular Epidemiology of Commonly Encountered Multi-Resistant Bacteria
A clinical trial, sponsored by University of Pittsburgh.
- Completed
- Registry status
- 300
- Enrollment target
NCT00275327: Completed study, sponsored by University of Pittsburgh.
NCT00275327 is a clinical trial that has completed, run by University of Pittsburgh. The registered enrollment target is 300 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00275327 has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- 300 participants
- Enrollment target
Study Summary
o determine if extended-spectrum beta-lactamases, plasmid-mediated AmpC beta-lactamases, carbapenemases, chromosomal mutations in ribosomal RNA or other mechanisms of resistance account for antibiotic resistance in commonly encountered Gram negative and Gram positive bacteria at UPMC. Also to determine the molecular epidemiology and in vitro susceptibility of multiply resistant organisms at UPMC and to relate this to antibiotic use in the institution.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2006-01 |
| Est. Completion | 2015-12 |
What the finished NCT00275327 record still lists
NCT00275327 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00275327 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00275327 about?
NCT00275327 is a clinical study titled "Mechanisms of Resistance and Molecular Epidemiology of Commonly Encountered Multi-Resistant Bacteria". o determine if extended-spectrum beta-lactamases, plasmid-mediated AmpC beta-lactamases, carbapenemases, chromosomal mutations in ribosomal RNA or other mechanisms of resistance account for antibiotic resistance in commonly encountered Gram negative and Gram positive bacteria at UPMC. Also to determ...
What is the current status of trial NCT00275327?
This trial is currently completed. The enrollment target is 300 participants. The study started on 2006-01. Estimated completion is 2015-12.
Who is sponsoring clinical trial NCT00275327?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia